PHILADELPHIA, March 6, 2017 /PRNewswire/ -- Aevi
Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced
today it will host a conference call and live audio webcast
on Tuesday, March 13, 2018 at 8:30 a.m. EDT to report financial results for the
fourth quarter and year ended December 31,
2017 and discuss recent business updates.
To access the conference call by phone, please dial (877)
870-4263 (domestic) or (412) 317-0790 (international) and request
to join the Aevi Genomic Medicine's Conference Call. The live
webcast can be accessed under "Events" in the Investors section of
the Company's website at www.aevigenomics.com or via the
following link.
https://www.webcaster4.com/Webcast/Page/1739/24714
The archived webcast will be available for 30 days in the
Investor section of Aevi Genomic Medicine website
at www.aevigenomics.com.
About Aevi Genomic Medicine, Inc.
Aevi Genomic
Medicine, Inc. is dedicated to unlocking the potential of genomic
medicine to translate genetic discoveries into novel therapies.
Driven by a commitment to patients with pediatric onset
life-altering diseases, the company's research and development
efforts leverages an internal genomics platform and an ongoing
collaboration with the Center for Applied Genomics (CAG) at The
Children's Hospital of Philadelphia (CHOP).
Forward-looking Statements
This release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995, which include all statements other
than statements of historical fact, including (without limitation)
those regarding the Company's financial position, its development
and business strategy, its product candidates and the plans and
objectives of management for future operations. The Company intends
that such forward-looking statements be subject to the safe harbors
created by such laws. Forward-looking statements are sometimes
identified by their use of the terms and phrases such as
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning, "expect," "believe," "will," "will likely," "should,"
"could," "would," "may" or the negative of such terms and other
comparable terminology. All such forward-looking statements are
based on current expectations and are subject to risks and
uncertainties. Should any of these risks or uncertainties
materialize, or should any of the Company's assumptions prove
incorrect, actual results may differ materially from those included
within these forward-looking statements. Accordingly, no undue
reliance should be placed on these forward-looking statements,
which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained herein to
reflect any change in the Company's expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based. As a result of these factors,
the events described in the forward-looking statements contained in
this release may not occur.
CONTACT:
Aevi Genomic Medicine, Inc.
Brian Piper
Brian.Piper@aevigenomics.com
Westwicke Partners
Chris Brinzey
339-970-2843
Chris.brinzey@westwicke.com
MEDIA INQUIRIES:
FTI Consulting
Irma Gomez-Dib
+1-212-850-5761
+1-415-706-9155
irma.gomez-dib@fticonsulting.com
View original
content:http://www.prnewswire.com/news-releases/aevi-genomic-medicine-to-host-conference-call-to-announce-fourth-quarter-and-year-end-2017-financial-results-300607746.html
SOURCE Aevi Genomic Medicine, Inc.